



(51) International Patent Classification:
C12N 5/07 (2010.01)

(21) International Application Number:
PCT/US2009/005510

(22) International Filing Date:
8 October 2009 (08.10.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/103,810 8 October 2008 (08.10.2008) US

(71) Applicant (for all designated States except US): IN-
TREXON CORPORATION [US/US]; 1872 Pratt Drive,
Blacksburg, VA 24060 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BEECH, Robert,
Patterson [US/US]; 9938 Zig Zag Road, Cincinnati, OH
45242 (US). REED, Thomas, D. [US/US]; 2905 Ash-
lawn Drive, Blacksburg, VA 24060 (US).

(74) Agents: COVERT, John, M. et al.; Sterne Kessler Gold-
stein & Fox PLLC, 1100 New York Avenue, Nw, Wash-
ington, DC 20005 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).


Published:

— without international search report and to be republished
upon receipt of that report (Rule 48.2(g))

— with sequence listing part of description (Rule 5.2(a))

(54) Title: ENGINEERED CELLS EXPRESSING MULTIPLE IMMUNOMODULATORS AND USES THEREOF

FIG. 1



(57) Abstract: This invention relates to the field of therapeutics. Most specifically invention provides methods of generating in vitro engi-
neered immune cells conditionally expressing interleukin-12 (IL- 12)
and one or more immunomodulators under the control of a gene expres-
sion modulation system in the presence of activating ligand and uses for
therapeutic purposes in animals.